title: Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
abstract: Patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis with less than 10 % of patients surviving 5 years. Most such patients cannot be rescued with currently available therapies, whatever the initial treatment they receive. Therefore, there is an urgent need for novel treatment options. Fortunately, over the past several years, an improved understanding of the biology of the disease has allowed the identification of rational molecular targets for therapeutic endeavors and the emergence of novel therapies has sparked great interest. This review will discuss the current treatment landscape for adult patients with relapsed and/or refractory ALL.
authors.affiliation: Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bayit Street, Jerusalem, 91031, Israel.
authors.forename: Aharon
authors.initials: A
authors.lastname: Ronson
authors.affiliation: Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bayit Street, Jerusalem, 91031, Israel.
authors.forename: Ariella
authors.initials: A
authors.lastname: Tvito
authors.affiliation: Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bayit Street, Jerusalem, 91031, Israel. rowe@jimmy.harvard.edu.|Technion, Israel Institute of Technology, Haifa, Israel. rowe@jimmy.harvard.edu.
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents
keywords: Acute lymphoblastic leukemia; Blinatumomab; Chimeric antigen receptor-T; Relapsed/refractory